Eye drops for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with 'wet' age-related macular degeneration (AMD), and the trial doctor confirms that the condition affects the central part of your vision (the macula).
- Your vision in the study eye is within a certain range (between roughly 20/80 and 20/200 on a standard eye chart). This vision loss is mainly due to wet AMD.
- You have either never had anti-VEGF injections (like Lucentis, Avastin, Eylea, or Vabysmo) in the study eye, or you have stopped them for a required time before starting the trial.
- You are able to put eye drops in your own eye (or have a caregiver do it) and are willing to follow the study schedule.
- You agree to use effective birth control (if you can have children) and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests a new eye drop treatment for people with wet age-related macular degeneration (AMD) who have already been treated with standard injections. The goal is to see if this new treatment can help maintain or improve vision and reduce the need for injections.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.